(Deamino-Cys1,D-Arg8)-Vasopressin acetate salt

Modify Date: 2024-01-02 17:31:23

(Deamino-Cys1,D-Arg8)-Vasopressin acetate salt structure	Common Name	(Deamino-Cys1,D-Arg8)-Vasopressin acetate salt
	CAS Number	16679-58-6	Molecular Weight	1069.217
	Density	1.6±0.1 g/cm3	Boiling Point	N/A
	Molecular Formula	C₄₆H₆₄N₁₄O₁₂S₂	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of (Deamino-Cys1,D-Arg8)-Vasopressin acetate salt

Desmopressin(DDAVP) is the synthetic analogue of the antidiuretic hormone arginine vasopressin. IC50 Value:Target: Vasopressin ReceptorThe antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. Desmopressin works by limiting the amount of water that is eliminated in the urine. Desmopressin binds to V2 receptors in renal collecting ducts, increasing water reabsorption. It also stimulates release of von Willebrand factor from endothelial cells by acting on the V2 receptor.

Name	desmopressin
Synonym	More Synonyms

Description	Desmopressin(DDAVP) is the synthetic analogue of the antidiuretic hormone arginine vasopressin. IC50 Value:Target: Vasopressin ReceptorThe antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. Desmopressin works by limiting the amount of water that is eliminated in the urine. Desmopressin binds to V2 receptors in renal collecting ducts, increasing water reabsorption. It also stimulates release of von Willebrand factor from endothelial cells by acting on the V2 receptor.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Vasopressin Receptor Research Areas >> Metabolic Disease Natural Products >> Others Peptides
References	[1]. Vande Walle J, Stockner M, Raes A, N?rgaard JP. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf. 2007 Sep;2(3):232-8. [2]. Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A. Blood Coagul Fibrinolysis. 2010 Oct;21(7):615-9. [3]. Sánchez-Luceros A, Meschengieser SS, Woods AI et al. Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history. Thromb Haemost. 2010 Nov;104(5):984-9. [4]. Alonso DF, Ripoll GV, Garona J et al. Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin. Curr Pharm Biotechnol. 2011 Nov;12(11):1974-80. [5]. Tsukamoto I. Recent patenting activities in the discovery and development of vasopressin V2 receptor agonists. Expert Opin Ther Pat. 2012 Jun;22(6):579-86.

Description

Related Catalog

Signaling Pathways >> GPCR/G Protein >> Vasopressin Receptor

Research Areas >> Metabolic Disease

Natural Products >> Others

Peptides

References

[1]. Vande Walle J, Stockner M, Raes A, N?rgaard JP. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf. 2007 Sep;2(3):232-8.

[2]. Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A. Blood Coagul Fibrinolysis. 2010 Oct;21(7):615-9.

[3]. Sánchez-Luceros A, Meschengieser SS, Woods AI et al. Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history. Thromb Haemost. 2010 Nov;104(5):984-9.

[4]. Alonso DF, Ripoll GV, Garona J et al. Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin. Curr Pharm Biotechnol. 2011 Nov;12(11):1974-80.

[5]. Tsukamoto I. Recent patenting activities in the discovery and development of vasopressin V2 receptor agonists. Expert Opin Ther Pat. 2012 Jun;22(6):579-86.

Density	1.6±0.1 g/cm3
Molecular Formula	C₄₆H₆₄N₁₄O₁₂S₂
Molecular Weight	1069.217
Exact Mass	1068.427002
PSA	486.01000
LogP	-5.82
Index of Refraction	1.713

HS Code	2937190090

HS Code	2937190090

Solid lipid particles for oral delivery of peptide and protein drugs III - the effect of fed state conditions on the in vitro release and degradation of desmopressin.

AAPS J. 16(4) , 875-83, (2014)

The effect of food intake on the release and degradation of peptide drugs from solid lipid particles is unknown and was therefore investigated in vitro using different fed state media in a lipolysis m...

Abnormal fluid homeostasis in apelin receptor knockout mice.

J. Endocrinol. 202(3) , 453-62, (2009)

The apelinergic system, comprised of apelin and its G protein-coupled receptor (APJ; APLNR as given in MGI Database), is expressed within key regions of the central nervous system associated with argi...

In vitro models for metabolic studies of small peptide hormones in sport drug testing.

J. Pept. Sci. 21(1) , 1-9, (2014)

Peptide hormones represent an emerging class of potential doping agents. Detection of their misuse is difficult due to their short half-life in plasma and rapid elimination. Therefore, investigating t...

DESAMINO-[D-ARG8]VASOPRESSIN

Desmopressin

Glycinamide, 1-[[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)-1,2-dithia-5,8,11,14,17-pentaazacycloeicos-4-yl]carbonyl]-L-prolyl-L-arginyl-

DDAVP

DESMOPRESSIN,HUMAN

Mep(mercaptopropionic acid)-YFQNCPdRG-NH2

DDAVP,HUMAN

[DEAMINO1,DARG8] VASOPRESSIN

M.W. 1069.22 C46H64N14O12S2

DESMOPRESSIN ACETATE PH. EUR.

[DEAMINO-CYS1,D-ARG8]-VASOPRESSIN

Adiuretin-SD

1-{[(4R,7S,10S,13S,16S)-7-(2-Amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-L-arginylglycinamide

Octostim

MINIRIN

MAP-TYR-PHE-GLN-ASN-CYS-PRO-D-ARG-GLY-NH2(DISULFIDE BRIDGE,MAP1-CYS6)